verdinexor

a selective inhibitor of nuclear export

Also Known As:

(2Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)prop-2-enehydrazide; 2-propenoic acid, 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-pyridinyl)hydrazide, (2Z)-; KPT-335; KPT335

Networked: 11 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shacham, Sharon: 4 articles (01/2016 - 01/2014)
2.	London, Cheryl A: 3 articles (08/2018 - 01/2014)
3.	Tripp, Ralph A: 3 articles (01/2018 - 09/2014)
4.	Landesman, Yosef: 3 articles (12/2014 - 07/2014)
5.	McCauley, Dilara: 3 articles (09/2014 - 01/2014)
6.	Borgatti, Antonella: 2 articles (08/2018 - 01/2014)
7.	Wilson, Heather: 2 articles (08/2018 - 01/2014)
8.	Howerth, Elizabeth: 2 articles (01/2016 - 09/2014)
9.	Johnson, Scott: 2 articles (01/2016 - 09/2014)
10.	Perwitasari, Olivia: 2 articles (01/2016 - 09/2014)

Related Diseases

1.	Infections 01/01/2016 - "In this study, in vivo efficacy of verdinexor was further evaluated in two animal models or influenza virus infection, mice and ferrets. " 09/01/2014 - "Thus, this study demonstrated that verdinexor is efficacious against influenza virus infection in vitro and in vivo." 01/01/2016 - "Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection." 01/01/2016 - "These findings support the anti-viral efficacy of verdinexor, and warrant its development as a novel antiviral therapeutic for influenza infection."
2.	Human Influenza (Influenza) 09/01/2014 - "Verdinexor was found to limit the replication of various strains of influenza A and B viruses, including a pandemic H1N1 influenza virus strain, a highly pathogenic H5N1 avian influenza virus strain, and a recently emerging H7N9 influenza virus strain. " 01/01/2016 - "Previously, we demonstrated the antiviral activity of a novel nuclear export inhibitor drug, verdinexor, to reduce influenza replication in vitro and pulmonary virus burden in mice. " 01/01/2016 - "These findings support the anti-viral efficacy of verdinexor, and warrant its development as a novel antiviral therapeutic for influenza infection." 01/01/2018 - "KPT-335 works to (1) block CRM1 (i.e., Chromosome Region Maintenance 1; exportin 1 or XPO1) mediated export of viral proteins critical for RSV and influenza pathogenesis; and (2) repress nuclear factor κB (NF-κB) activation, thus reducing cytokine production and eliminating virus-associated immunopathology. "
3.	Neoplasms (Cancer) 01/01/2022 - "In the present study, we observed that verdinexor inhibited the proliferation and migration of EC cells in vitro and suppressed tumor growth in vivo. " 01/01/2014 - "This study provides evidence that the novel orally bioavailable XPO1 inhibitor KPT-335 is safe and exhibits activity in a relevant, spontaneous large animal model of cancer. " 01/01/2014 - "Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study." 08/12/2021 - "Cell proliferation assays, colony formation assays, apoptosis assays, cell cycle analysis were performed to analyze the anti-tumor effects of verdinexor (KPT-335) in vitro. " 08/12/2021 - "In vivo anti-tumor effects of verdinexor were studied in a neuroblastoma xenograft model. "
4.	Osteosarcoma (Osteogenic Sarcoma) 06/01/2021 - "The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines." 06/01/2021 - "In the present study, we sought to characterize the expression of XPO1 in primary canine osteosarcoma (OS) tumour samples, OS cell lines and normal osteoblasts and evaluate the in vitro activity of verdinexor alone or in combination with doxorubicin. " 01/01/2014 - "Canine tumor cell lines derived from non-Hodgkin lymphoma (NHL), mast cell tumor, melanoma and osteosarcoma exhibited growth inhibition and apoptosis in response to nanomolar concentrations of SINE compounds; NHL cells were particularly sensitive with IC50 concentrations ranging from 2-42 nM. A Phase I clinical trial of KPT-335 was performed in 17 dogs with NHL (naive or relapsed), mast cell tumor or osteosarcoma. "
5.	Melanoma (Melanoma, Malignant) 07/15/2014 - "The present study sought to characterize the biologic activity of an orally bioavailable selective inhibitor of nuclear export (SINE), KPT-335, against canine melanoma cell lines as a prelude to future clinical trials in dogs with melanoma. " 07/15/2014 - "KPT-335 demonstrates biologic activity against canine melanoma cell lines at physiologically relevant doses, suggesting that KPT-335 may represent a viable treatment option for dogs with malignant melanoma." 07/15/2014 - "We evaluated the effects of KPT-335 on 4 canine malignant melanoma cell lines and found that KPT-335 inhibited proliferation, blocked colony formation, and induced apoptosis of treated cells at biologically relevant concentrations of drug. " 07/15/2014 - "Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines." 01/01/2014 - "Canine tumor cell lines derived from non-Hodgkin lymphoma (NHL), mast cell tumor, melanoma and osteosarcoma exhibited growth inhibition and apoptosis in response to nanomolar concentrations of SINE compounds; NHL cells were particularly sensitive with IC50 concentrations ranging from 2-42 nM. A Phase I clinical trial of KPT-335 was performed in 17 dogs with NHL (naive or relapsed), mast cell tumor or osteosarcoma. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	verdinexor
3.	Exportin 1 Protein
4.	Proteins (Proteins, Gene)
5.	Doxorubicin (Adriamycin)
6.	Cytokines
7.	Viral Proteins
8.	Indicators and Reagents (Reagents)
9.	KPT-185